GAMMA Investing LLC Increases Position in Royalty Pharma plc (NASDAQ:RPRX)

GAMMA Investing LLC increased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 31.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,471 shares of the biopharmaceutical company’s stock after acquiring an additional 590 shares during the quarter. GAMMA Investing LLC’s holdings in Royalty Pharma were worth $63,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new stake in Royalty Pharma in the 2nd quarter valued at about $250,000. Daiwa Securities Group Inc. boosted its position in Royalty Pharma by 4.5% during the 2nd quarter. Daiwa Securities Group Inc. now owns 27,694 shares of the biopharmaceutical company’s stock worth $730,000 after purchasing an additional 1,180 shares during the period. American Century Companies Inc. increased its holdings in Royalty Pharma by 13.0% in the 2nd quarter. American Century Companies Inc. now owns 60,468 shares of the biopharmaceutical company’s stock valued at $1,595,000 after purchasing an additional 6,955 shares in the last quarter. Forsta AP Fonden raised its position in Royalty Pharma by 138.8% in the second quarter. Forsta AP Fonden now owns 235,900 shares of the biopharmaceutical company’s stock valued at $6,221,000 after purchasing an additional 137,100 shares during the period. Finally, Meeder Advisory Services Inc. lifted its position in Royalty Pharma by 12.7% during the 2nd quarter. Meeder Advisory Services Inc. now owns 8,223 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 926 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RPRX has been the subject of several recent analyst reports. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $41.67.

Royalty Pharma Stock Up 12.6 %

Shares of RPRX stock opened at $29.49 on Monday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a market cap of $17.38 billion, a PE ratio of 15.28, a price-to-earnings-growth ratio of 4.36 and a beta of 0.47. The business’s fifty day moving average is $25.94 and its 200-day moving average is $27.05. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $31.66.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.98%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s dividend payout ratio (DPR) is presently 43.52%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.